The landscape of diabetes management is continually evolving, with innovative therapies that offer improved efficacy and patient experience. Among these advancements, tirzepatide has emerged as a revolutionary treatment option, demonstrating remarkable potential in Rebrand Tirzepatide GLP-1 Peptide clinical trials. As a dual GLP-1 and GIP receptor